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Fractional exhaled nitric oxide (FeNO) is a convenient, non-invasive method for the assessment of active, mainly
Th2-driven, airway inflammation, which is sensitive to treatment with standard anti-inflammatory therapy.
Consequently, FeNO serves as a valued tool to aid diagnosis and monitoring in several asthma phenotypes.
More recently, FeNO has been evaluated in several other respiratory, infectious, and/or immunological
conditions. In this short review, we provide an overview of several clinical studies and discuss the status of
potential applications of NO measurements in clinical conditions beyond asthma.
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I
n asthma, fractional exhaled nitric oxide (FeNO) is
a well-established, non-invasive online method for
the assessment of active, mainly T-helper 2 (Th2) -driven
airway inflammation, often associated with airway eosi-
nophilia, which is sensitive to treatment with inhaled
corticosteroids (ICSs) (1). In the past two decades, this
method has been further refined and portable equipment
has been developed and validated against chemilumines-
cence devices (2). Consequently, for more than a decade,
FeNO has been implicated as avalued tool in the diagnosis
and monitoring of corticosteroid-sensitive asthma.
More recently, FeNO has been evaluated in several
other respiratory, allergic, infectious, and/or immunologi-
cal conditions. In this short review, we provide an overview
of studies applying FeNO measurements in several clinical
conditions (Table 1) and underlying pathophysiological
and biological mechanisms. In addition, potential clinical
applications of NO measurements and future needs be-
yond asthma will be discussed.
NO in chronic obstructive pulmonary disease
Persistent airway inflammation in both large and small
airways is a hallmark of chronic obstructive pulmonary
disease (COPD), causing progressive airflow limitation,
airway remodeling, and dyspnea. Several studies have
underscored the importance of the underlying systemic
inflammation in the pathophysiology of COPD (35). The
presence of concomitant systemic inflammation seems to
be related to disease severity and frequency of exacerba-
tions and can be measured as an increment of circulating
cytokines (IL-6, TNF-a), chemokines (IL-8), and acute
phase proteins, such as C-reactive protein (CRP) (68). In
line with the chronic inflammation, increased expression
of inducible nitric oxide synthase (iNOS) has been
demonstrated in both central and peripheral airways of
COPD patients (9). FeNO levels in unselected COPD
patients are not different from healthy controls, whereas
subgroups with increased FeNO levels have been reported
(10). Patients with severe COPD have overall lower FeNO
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levels than patients with milder disease (11). In addition,
smoking history must be taken into account as smoking
affects FeNO levels. Current smokers with COPD had sig-
nificantly lower FeNO levels compared to ex-smoking
COPD patients (12). Peripheral airway inflammation in
COPD can be reflected by increased alveolar NO levels
(CalvNO) (13, 14). Surprisingly, CalvNO was not sup-
pressed by systemic or ICSs in ultrafine particles (15).
In asthma, FeNO has been regarded as a marker of ICS
responsive, Th2driven airway inflammation, often asso-
ciated with airway eosinophilia, with increased FeNO
levels during asthma exacerbations. In COPD, exacerba-
tions often follow respiratory infections that can be
reflected by increases in FeNO levels (16) and systemic
inflammation markers (17). In a recent study about ex-
smoking COPD patients, FeNO was shown to correlate
with sputum eosinophilia during exacerbations, and hence
acted as predictor of ICS-responsiveness in these patients
(18). In several COPD studies, FeNO had only a weak
predictive role to detect improvement in symptoms or
lung function after starting treatment with corticosteroids
(12, 19, 20). An analysis of published controlled rando-
mized studies using blood eosinophils as an algorithm
to treat COPD exacerbations with prednisolone showed
that a blood eosinophil count ]2% was associated with
a significantly better response to systemic prednisolone
compared to a blood eosinophil count B2% (21).
More recently, a subgroup of patients with asthma
COPD overlap syndrome (ACOS) has gained attention
as it is now recognized that these patients have more
frequent and more severe exacerbations (22). This COPD
phenotype also has less emphysema, increased airway
wall thickening, with often strongly variable FEV1 and
non-specific airway hyperresponsiveness (23). ACOS has
been associated with polymorphism in the gene GPR65
(23), which is associated with eosinophil activation. So
far, FeNO has not been specifically studied in ACOS
and such studies are needed to understand the value of
FeNO measurements in this phenotype.
Based on recent data, FeNO may have a role in the
phenotyping and monitoring of distinct COPD subsets,
including in predicting corticosteroid responsiveness in
ACOS patients and those with eosinophilic airway in-
flammation (24). Implementation of FeNO measurements
in the management of COPD needs further investigation.
NO in cystic fibrosis
Cystic fibrosis (CF) is characterized by a defect in a
chloride ion channel across the respiratory epithelium,
among other organs, that leads to increased mucus viscosity,
accumulation of mucus, chronic infection, and inflamma-
tion. FeNO levels are reported to be decreased in CF, with
further decreases following a mouthwash (25). The degree
of chloride ion transport impairment appears to relate
to the decrease in FeNO levels (26).
The lower NO production is probably related to the
reduction of NO production as both constitutional (27, 28)
and inducible NOS (29, 30) activity is reduced. Further-
more, asymmetric dimethylarginine (ADMA), an endo-
genous NO synthase inhibitor, is increased in the sputum
of CF patients (31), whereas arginine, a substrate for NO
production, is reduced (32). Another FeNO-decreasing
mechanism in CF might be an increased catabolism of NO
(33). Lower levels of FeNO can also be due to mechanical
factors as increased secretions might reflect a diffusion
barrier for NO. Reduced airway caliber might relate to
a lower bronchial epithelial area in contact with airway
lumen and therefore lower FeNO (34). Furthermore,
increased secretions might cause a diffusion barrier and
further reduce exhaled NO. Previous animal studies
argued for a role of NO deficiency in impaired airway
relaxation in CF which might contribute to the airway
obstruction (35). Interestingly, the low FeNO levels seen in
CF can be further reduced by systemic corticosteroids (36).
Table 1. Summary of nitric oxide measurements in different clinical conditions
FeNO CalvNO nNO
Asthma Normal/increased Normal/increased Normal/increased
COPD Normal/increased Increased NS
CF Normal/decreased Contradictory results Decreased
PCD Normal/decreased Contradictory results Decreased
Allergic rhinitis Normal/increased Normal NS
BPD Normal/decreased Decreased NS
HPS Decreased Increased NS
PAH Decreased Increased NS
SSc Normal/decreased Increased NS
Rhinovirus infection Increased NS NS
Allograft rejection Increased NS NS
NS: not studied, COPD: chronic obstructive pulmonary disease, CF: cystic fibrosis, PCD: primary ciliary dyskinesia, BPD:
bronchopulmonary dysplasia, HPS: hepatopulmonary syndrome, PAH: pulmonary arterial hypertension, SSc: systemic sclerosis.
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In CF, supplementation with L-arginine by infusion
(37), oral administration (38), or inhalation (39, 40) re-
sulted in increased FeNO levels. Antibiotic treatment
resulted in increased FeNO levels in one study (41), but
this was not reproduced in another study, although a
subgroup of patients appeared to exhibit an increase in
FeNO levels (42). Dornase alpha treatment did not sig-
nificantly affect FeNO in a small-scale study (43), but
changes in FeNO levels related to changes in lung function
in dornase alpha-treated-CF patients.
Several contradictory reports on levels of CalvNO
in CF patients have been published (44, 45). CalvNO
appeared to relate to ventilatory efficiency during exer-
cise and airway obstruction in one study (46), but more
studies are needed to confirm these findings.
Even if there is evidence for decreased levels of FeNO
in CF patients with a link toward at least lower lung
function, there is still lack of data regarding the role of
repeated FeNO measurements, for example, in the annual
follow-up or follow treatment with antibiotics in CF.
Presently, there is no evidence for a role for CalvNO
measurements in the management of CF.
NO in bronchopulmonary dysplasia
Prematurity and its main respiratory complication, bron-
chopulmonary dysplasia (BPD), are potentially associated
with lifelong lung function abnormalities, but the inflam-
matory component is most prominent during the neonatal
period. Preterm infants with BPD show a weak postnatal
increase in FeNO on day 28 as well as at a postmenstrual
age of 49 weeks, particularly in those developing moder-
ate or severe BPD (47, 48). Children with BPD are at
increased risk for respiratory symptoms, including wheeze,
cough, and dyspnea, even though the inflammatory
component often diminishes during the first years. In a
follow-up study of a subgroup of 53 previously preterm
children (aged 1091.5 years, 28 with BPD) 60% wheezed
at age B2 years, but only 13% wheezed in the past year.
In addition, non-specific airway hyperresponsiveness was
present in 49% despite normal FeNO levels (49). At school
age, children with very low birth weight (with or without
BPD) showed lung function abnormalities characterized
by airway obstruction, hyperinflation, and diffusion im-
pairment, with reduced or normal FeNO levels (5053).
CalvNO levels in schoolchildren with BPD were similar to
preterm children without BPD and term children (52).
Nevertheless, in atopic children with very low birth weight,
non-specific airway hyperresponsiveness was related to
NO levels, derived from central airways (bronchial flux)
rather than from peripheral airways (CalvNO). It is likely
that the airway hyperresponsiveness is related to the ato-
pic phenotype rather than to the inflammatory process
due to prematurity (54). Exhaled breath temperature,
another measure of airway inflammation, was signifi-
cantly lower in BPD survivors than in asthmatic patients
(55). Many patients born prematurely, who developed
BPD as neonates, are now approaching adulthood.
Patients with chronic respiratory symptoms who were
born prematurely should undergo comprehensive lung
function testing including FeNO measurements. The
pathophysiology of BPD is not identical to that of asthma
and standard treatment for asthma is therefore ineffective
in BPD. FeNO measurements may be useful to differenti-
ate BPD from asthma.
NO in respiratory infections
The influence of respiratory infections on FeNO has not
been studied in detail, although infections of presumed
viral origin were early recognized to be associated with
an increase in FeNO levels (56, 57). Later studies have
indicated that this increase in FeNO is primarily related
to rhinovirus infections (5860), whereas both infections
with respiratory syncytial virus (61, 62) and influenza
virus (63) seem to be associated with reductions rather
than increases in FeNO levels. The reason for increased
FeNO levels in rhinovirus infections is poorly studied,
but may involve upregulation of interferons causing in-
creased iNOS expression in the bronchial epithelium via
activation of signal transducer and activator of transcrip-
tion (STAT)-1 (56). In contrast to rhinovirus infections,
bacterial pneumonias are not generally related to in-
creased FeNO levels (64), and neither is the exposure
to endotoxin and other bacterial components (6567).
Interestingly, in lung transplant recipients (LTRs), bac-
terial pneumonias have been shown to be associated with
increased FeNO levels, but whether this is a response seen
uniquely in these patients is presently unknown.
In summary, FeNO measurements do not seem to
be useful in the management of respiratory infections. It
is suggested that if a patient with (suspected) asthma
reports recent or ongoing symptoms of common cold, the
patient should be reexamined with regard to FeNO after
a symptom-free interval of at least 34 weeks.
NO in allograft rejections
More than 15 years ago, Silkoff et al. (68) showed
increases in FeNO levels within 20 days before or after
a suspected acute cellular rejection in LTRs, but not in
patients with stable Bronchiolitis Obliterans Syndrome
(BOS). In another study, Fisher et al. (69) showed in-
creased FeNO levels in patients with BOS grade 1 (early
stage), but not at later stages (BOS grades 2 and 3).
Several later studies showed elevated FeNO levels in
unstable BOS and in unstable non-BOS patients who later
developed BOS (7072). The increased FeNO levels in
these situations were relatively stable and not related
to concomitant pulmonary infections which cause only
transient (23 weeks) increases in FeNO levels in LTRs
(73). Neurohr et al. (72) showed a negative predictive
Clinical application of nitric oxide measurements
Citation: European Clinical Respiratory Journal 2015, 2: 28517 - http://dx.doi.org/10.3402/ecrj.v2.28517 3
(page number not for citation purpose)
value of 97% for FeNO in predicting the development of
BOS. Changes in FeNO, more specifically an increase
of 10 ppb, had a very good specificity for detecting an
acute complication after lung transplantation (74).
The mechanism underlying increased NO formation
seen in unstable patients after lung transplantation is not
entirely clear. Early on, Gabbay et al. (75) reported that
increased iNOS expression in the bronchial epithelium of
patients with BOS which positively correlated with FeNO.
In contrast to neutrophilic asthma, FeNO has been shown
to strongly correlate with neutrophil counts in bronchoal-
veolar lavage (BAL) fluid of LTRs (72, 75), although the
biological link between neutrophilia and increased iNOS
expression in bronchial epithelium is presently unknown.
Another study showed increased sputum eosinophils and
neutrophils in BOS compared to non-BOS patients, which
was negatively correlated with lung function parameters
(76). A similar relationship to BOS has also been found
for both these cell types when measured in BAL fluid
(77). These findings may indicate that both eosinophilic
and neutrophilic inflammation contribute to the develop-
ment of BOS. However, a recent study showed that BAL
eosinophilia, but not BAL neutrophilia, relates to both
mortality and the development of chronic lung allograft
dysfunction (BOS and restrictive allograft syndrome) in
LTRs (78). Interestingly, one study has suggested that
interleukin (IL)-13 is pivotal in the development of BOS
(79). Thus, the latter two studies indicate that Th2-driven
mechanisms are important for allograft dysfunction in
LTRs. These data suggest that FeNO measurement in the
management of LTRs warrants further investigation.
NO in scleroderma and interstitial lung disease
Systemic sclerosis (SSc) is a connective tissue disorder of
unknown etiology that is often complicated by pulmonary
involvement, with pulmonary arterial hypertension (PAH)
and interstitial lung disease (ILD) being the major causes
of death. In early studies, it has been presented that FeNO
is increased in SSc patients (80), and specifically in asso-
ciation with fibrosing lung disease (81, 82). In contrast,
other studies showed lower FeNO levels in SSc patients
with ILD compared to patients without ILD (83, 84).
Patients with SSc and PAH show relatively low FeNO
values suggesting the important role of NO in regulating
pulmonary vascular resistance in SSc (82, 85). In some of
the early studies reporting increased FeNO levels, higher
exhalation flow rates have been used (e.g. 250 mL/s) and,
therefore, peripheral airways have probably been sampled
to larger extent (82, 83). Later, several studies indeed
showed convincing increases in CalvNO levels, whereas no
increase in FeNO could be detected (8689). CalvNO
levels are specifically increased in early SSc, suggested to
reflect early inflammatory lung involvement in SSc (89). In
other studies, increased CalvNO was found to be related to
the grade of ILD (87) and alveolitis (90), and has been
shown to be a valuable tool for predicting ILD (88) and
pulmonary deterioration (91).
So far, application of FeNO measurement in the man-
agement of SSc and ILD patients is not supported by
data, whereas increased CalvNO concentrations could
be used to non-invasively assess the extent of ILD in
conditions including SSc.
NO in pulmonary arterial hypertension
PAH is characterized by an increase in pulmonary arterial
pressure and in pulmonary vascular resistance. This is
probably because of an imbalance of local vasodilators
and vasoconstrictors. For example, elevated levels of
endothelin-1, with vasoconstrictor properties, and de-
creased levels of NO, with vasodilator properties, or NO
metabolites have been described (92). Idiopathic PAH
(IPAH), that is, PAH without an identifiable cause, is the
most commonly studied condition. Decreased FeNO levels
have been generally found in patients with PAH and this
appears to be especially the case in IPAH (93). The
underlying mechanisms might include the lack of sub-
strate, as supplementation with L-arginine increased NO
levels (94), and inhibited NOS-related NO production, as
higher levels of asymmetric dimethylarginine have been
described in IPAH (95).
FeNO levels have been shown to negatively correlate
with pulmonary arterial pressure, assessed by echocardio-
graphy (96). Recent data in a PAH animal model showed
a correlation between treatment-related changes in FeNO
and pulmonary arterial pressure (97). Studies in humans
are in line with these animal data. An increase in FeNO
levels in patients with PAH under treatment was found to
be related with the decrease in pulmonary arterial pressure
and a prognostic factor for survival (98). Similarly, FeNO
levels increased after treatment with endothelin-receptor
antagonist (99), prostacyclin (100), or phosphodiesterase
5-inhibition (101). Furthermore, PAH patients who respon-
ded to therapy with prostacyclin showed higher baseline
FeNO levels (100).
Presently, insufficient evidence exists for recommending
routine use of FeNO measurements to predict or follow
response to specific PAH-therapy and hence, additional
studies need to be conducted.
NO in hepatopulmonary syndrome
In patients with liver cirrhosis and/or portal hypertension,
hepatopulmonary syndrome (HPS) is characterized by an
abnormal oxygenation (increased age-corrected alveolar
arterial oxygen difference) due to intrapulmonary vascular
dilatations (on contrast-enhanced echocardiography or frac-
tional brain uptake after lung perfusion of technetium-
99m macroaggregated albumin lung scanning) (102). The
first reports of increased FeNO levels in patients with
liver cirrhosis and HPS are those from Cremona et al.
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(103) and Rolla et al. (104). Both studies showed a sig-
nificant decrease in FeNO levels and improvement in
oxygenation following liver transplantation (103, 105),
still the only cure for HPS. It must be stressed that the
technique used to collect exhaled air in these studies
was markedly different from current recommendations.
More recently, by using the technique of multiple flows
analysis of NO output, Delclaux et al. (106) demonstrated
that the increased FeNO levels previously reported in
cirrhosis are of alveolar origin and correlate with the
alveolararterial oxygen difference. Through additional
measurement of NO lung transfer, Degano et al. (107)
were able to demonstrate that the increase in CalvNO in
cirrhotic patients is due to increased NO output from
the alveoli and not due to the decreased lung transfer
factor of NO. They showed that in these patients alveo-
lar NO production was associated with hyperdynamic
circulatory syndrome, but not with arterial oxygenation
impairment. Authors suggest that the lack of correlation
between CalvNO and oxygenation impairment observed
in their patients may depend on differences in study popu-
lations as in previous studies patients had more severe
HPS. Alternatively, the relationship between CalvNO
and hyperdynamic circulatory syndrome suggests that
NO production may be similarly increased in both the
pulmonary and the systemic vessels in cirrhotic patients.
In conclusion, the above reported observations support
the theory that NO plays an important role in the patho-
physiology of HPS. However, the enthusiasm for inhib-
iting NO as therapeutical strategy in HPS has been
mitigated by the study of Gomez et al. (108), who reported
that inhibition of pulmonary NO-synthase activity (caus-
ing acute inhibition of pulmonary NO production) by
nebulized NG-nitro-L-arginine methyl ester (L-NAME)
had no effect on hypoxemia in patients with HPS.
Whether FeNO or CalvNO measurements can serve to
assess the development and the severity of HPS or in the
management of this condition awaits further investigation.
Nasal NO
In parallel to exhaled NO measurements, the value of
nasal NO (nNO) samplings in clinical conditions includ-
ing allergy, primary ciliary dyskinesia (PCD), and CF
has been investigated. nNO is produced in the upper
airway compartment, especially within the epithelium of
the paranasal sinuses, and can be reproducibly sampled
(109, 110). Currently, the best-validated sampling method
comprises aspiration of nNO at a constant transnasal
airflow rate as detailed in the last international recom-
mendations (111). Depending on the sampling flow rates,
normal values of nNO are within the range of approxi-
mately 100800 ppb in both children (617 years) (112)
and adults (113).
In patients with untreated allergic rhinitis (AR), nasal
eosinophilia has been shown to be accompanied by in-
creased nNO levels as a result of enhanced iNOS expres-
sion within the nasal epithelium (114). Pro-inflammatory
stimuli such as intranasal allergen challenge (further)
increase nNO in sensitized patients (110), whereas anti-
inflammatory therapy reduces nNO (115). However,
conflicting data exist on the reproducibility of nNO
measurements and its applicability as biomarker of aller-
gic disease. Moody et al. (116) performed weekly nNO
measurements in 38 patients with perennial rhinitis during
3 weeks and found weak intrasubject repeatability with no
difference in nNO levels between allergic patients and non-
allergic individuals. Furthermore, nNO did not reflect
disease activity in the allergic patients (116).
In CF, low nNO levels have been reported (117, 118).
In some studies, lower nNO levels were associated with
increased systemic inflammation, assessed by CRP (119).
Furthermore, lower nNO levels were related with coloni-
zation with Staphylococcus aureus (120). Keen et al. (121)
found lower nNO levels in pancreatically insufficient CF
patients, with further decreases if their airways were colo-
nized with Pseudomonas aeruginosa. In contrast, no relation
with Pseudomonas aeruginosa was found in another study in
CF (118).
In patients with PCD, low nNO levels have been re-
producibly measured in several studies (122). Using the
handheld device at a nasal flow rate of 5 mL/s, showed
a reasonable intrasubject repeatability (coefficient of varia-
tion 15%), and an excellent sensitivity (95%) and speci-
ficity (100%) for PCD screening in a validation study (123).
Two recent reports suggest a value for monitoring of
nNO in asthma to evaluate asthma control (124, 125). In
these studies, nNO levels were negatively related to asthma
control both in an adult population enriched with sub-
jects with concomitant rhinosinusitis (124) and in children
and young adults with asthma (125).
In summary, although promising in some conditions,
especially in PCD and allergy, nNO measurements in
routine diagnosis and clinical disease monitoring still
awaits validation.
Future perspectives
For additional future applications of FeNO in other
(respiratory) conditions, we need to more precisely define
the cut off values and potential confounders. A high or
low value in one condition does not necessarily apply
in another. Taking smokers with COPD as an example:
smoke exposure suppresses FeNO. However, within
the group, it is clear that patients responding to ICS
have relatively higher FeNO values compared to non-
responders (126). Thus a ‘high’ FeNO level in a smoker
may be different from a non-smoker, possibly due to
down-regulation of both inducible and constitutive NO
production. In addition, as some of the potential future
applications covered in the present review, such as PCD
and CF, prevail in children, it should be highlighted that
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FeNO cut off values should also be better defined in
this population (127).
According to current recommendations, FeNO is mea-
sured at a flow rate of 50 mL/s, reflecting NO production
from the central airways (1). Measuring NO at flow rates
ranging from 10 to 300 mL/s allows the assessing of NO
production in the more distal airways (128). Increase in
CalvNO indicates uncontrolled Th2-driven inflammation
within peripheral airways. Patients already on ICS treat-
ment can thus be switched to ultrafine particles ICS and
sometimes the addition of systemic corticosteroids may be
effective (129). However, presence of peripheral airways
constriction limiting axial diffusion might lead to contra-
dictory results with lower CalvNO levels not excluding
distal inflammation (130, 131). Whether CalvNO can be
used on an individual basis in the clinical setting needs to
be established. Furthermore, the method to be used to
estimate CalvNO, as new methods have been proposed
(132), as well as the need to assess peripheral obstruction in
interpreting CalvNO, highlight a need for consensus on
which regression model should be used and how to best
estimate NO-contribution from different lung compart-
ments (133). Further evaluation and validation of these
parameters is urgently needed to establish the use of
relevant inflammatory markers that can be used in clinical
practice and as outcome measures in clinical trials.
Partly for economic reasons and limited availability,
FeNO is presently measured only within a limited number
of clinical settings and only at a few time points. However,
as disease activity shows day to day variation, and
even variation within the same day, it is desirable to per-
form more frequent measurements. An increased diurnal
variability in FeNO levels was associated with loss of
asthma control whereas peak flow variability did not
differ between controlled and uncontrolled asthmatics
(134). We also need to know whether NO measurements
on a regular, preferably daily, basis can help to predict a
deteriorating disease beyond asthma. For this purpose,
cheaper and easily accessible/applicable home measure-
ment devices are indispensable.
Conclusions
Still today, the majority of clinical decision making is being
based on symptom control and lung function parameters.
For the future, we will need reliable and simply measur-
able biomarkers that can guide our clinical and treatment
decisions and help us to monitor treatment effects as well
as predicting future deteriorations. Together with blood
eosinophils, FeNO is the most commonly used biomarker
not only in research but also in clinical practice. In asthma,
the clinical importance of FeNO as a marker of Th2-driven
inflammation that is likely to respond to ICSs is well-
established. However, the role of FeNO in other obstruc-
tive airway diseases such as COPD and ACOS remains
to be further validated following initial studies showing
that increased FeNO levels can predict corticosteroid
responsiveness (24, 135). In other respiratory conditions,
such as CF, PCD, and PAH, low NO levels (nNO and/or
FeNO) may be valuable diagnostic or disease monitoring
tools. The feasibility and clinical applicability of partition-
ing FeNO contributions from peripheral and central
airways needs to be further established.
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